Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Utility of the Signal-to-Cutoff Ratio of Reactive HIV Antigen/Antibody Screening Tests in Guiding Emergency Physician Management.

Journal of acquired immune deficiency syndromes (1999)·2022
Same author

Clinician-ordered peripheral blood smears have low reimbursement and variable clinical value: a three-institution study, with suggestions for operational efficiency.

Diagnostic pathology·2020
Same author

Liquid plasma: A solution to optimizing early and balanced plasma resuscitation in massive transfusion.

The journal of trauma and acute care surgery·2020
Same author

Photo Quiz: A 27-Year-Old Male with an "Itchy Rash" for 3 Months.

Journal of clinical microbiology·2019
Same author

Answer to September 2019 Photo Quiz.

Journal of clinical microbiology·2019
Same author

Draft Genome Sequences of Four NDM-1-Producing Klebsiella pneumoniae Strains from a Health Care Facility in Northern California.

Genome announcements·2015

Related Experiment Video

Updated: Jun 21, 2026

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Liver disease, coagulation testing, and hemostasis.

Valerie L Ng1

  • 1Clinical Laboratory, Highland General Hospital, 1411 East 31st Street, Oakland, CA 94602, USA. vang@acmedctr.org

Clinics in Laboratory Medicine
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Coagulation tests in liver disease patients often show abnormalities but do not predict bleeding risk. Fresh frozen plasma (FFP) administration based on these tests is ineffective for preventing bleeding.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Area of Science:

  • Hepatology
  • Hematology
  • Transfusion Medicine

Background:

  • Coagulation testing abnormalities are common in patients with liver disease.
  • Current practices often rely on outdated thresholds for blood product administration.

Purpose of the Study:

  • To review the evidence on coagulation testing in liver disease.
  • To evaluate the correlation between test results and actual hemostasis.
  • To assess the efficacy of fresh frozen plasma (FFP) in preventing bleeding.

Main Methods:

  • Literature review of studies on coagulation tests in liver disease.
  • Analysis of evidence linking test abnormalities to bleeding risk.
  • Examination of the rationale and effectiveness of FFP administration protocols.

Main Results:

  • Coagulation test abnormalities in liver disease lack correlation with hemostasis and do not predict bleeding.
  • The "1.5x" prothrombin time/international normalized ratio threshold for FFP/FP administration is historically inaccurate and ineffective.
  • FFP/FP does not correct minimally prolonged clotting times or adequately prevent bleeding from procedures like liver biopsy.

Conclusions:

  • Rethinking the interpretation and clinical utility of coagulation tests in liver disease is necessary.
  • Current transfusion strategies for FFP/FP based on standard coagulation parameters are not supported by evidence.
  • Alternative approaches to managing bleeding risk in liver disease patients should be explored.